NCT07917715Not yet recruiting
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
MacuMira Microcurrent Electrical Stimulation and Dark Adaptation in Dry Age-Related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Age-related macular degeneration (AMD) is an eye condition that affects the retina and can lead to progressive vision loss. This study will evaluate the effects of MacuMira microcurrent stimulation on dark adaptation in adults with intermediate dry AMD. Participants will receive four in-office treatment sessions over 10 to 14 days. Dark adaptation and other measures of visual function and retinal health will be assessed before treatment and at one and three months after treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 30 Oct 2026
- Start date
- 4 Nov 2026
- Primary completion date
- 16 Aug 2027
- Lead sponsor
- Clarity Eye Institute
- Diseases
- Macular degeneration
- NCT number
- NCT07917715
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 4 Nov 2026 to the primary completion date, 16 Aug 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of neovascular (wet) AMD or other macular or retinal diseases, including epiretinal membrane (ERM) or diabetic retinopathy.
- Presence of other ocular or systemic conditions that may confound central visual function (e.g., advanced glaucoma or optic neuritis) or study assessments (e.g., dementia).
Other
- Presence of geographic atrophy.
- Intolerability to MacuMira treatment.
- Baseline Rod Intercept Time (RIT) outside the eligibility range of 8.5 to 30 minutes.
Who the study is looking for
- Adults ≥18 years of age.
- Diagnosis of intermediate nonexudative age-related macular degeneration (AMD), according to the Beckman Classification.
- Preliminary best-corrected visual acuity (BCVA) of 20/30 to 20/100 in the study eye.
- Ability to provide informed consent and attend all required study visits over approximately 3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clarity Eye Newmarket Coordinator of this site? Confirm its status | Newmarket | Canada | Unknown status |
| Clarity Eye Scarborough Coordinator of this site? Confirm its status | Scarborough Village | Canada | Unknown status |
| Clarity Eye Vaughan Coordinator of this site? Confirm its status | Vaughan | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.